|

Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter

RECRUITINGSponsored by JW Medical Systems Ltd
Actively Recruiting
SponsorJW Medical Systems Ltd
Started2024-05-10
Est. completion2025-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world. The study population was patients with primary coronary vascular lesions with a blood vessel diameter of 2.0mm-2.75mm.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years;
* Primary coronary artery stenosis with a vessel diameter of 2.0 mm to 2.75 mm;
* Patients with residual stenosis of ≤ 30 percent after pretreatment and ≤ type B dissection; Patients who voluntarily participate in and sign the informed consent form, and who are willing to undergo follow-up as required by the protocol.

Exclusion Criteria:

* Pregnant or lactating females;
* Patients with cardiogenic shock;
* Patients with severe congestive heart failure or severe heart failure with NYHA class IV;
* Patients with severe valvular heart disease;
* Patients with a life expectancy of less than 24 months or factors that make clinical follow-up difficult;
* Patients who are considered unsuitable for inclusion by the investigator for other reasons.
* Those who are known to be allergic to melcrolimus and contrast media.

Conditions2

Coronary Artery DiseaseHeart Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.